Compare Medpace Holdings Inc (MEDP) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nasdaq100 ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Nasdaq100 ETF trades at $751.31 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 30.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 48,326,518). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Nasdaq100 ETF for 162 Days on average.
| MEDP | QQQ | |
|---|---|---|
Market Cap | $16.82B | $506.92B |
Volume | 223,093 | 48,326,518 |
Sector | Health | — |
52-Week High | $630.19 | $759.66 |
52-Week Low | $393.42 | $558.34 |
Typical Hold Time | 14 Days | 162 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
QQQ trades at $750.47, down 0.96% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights QQQ's strong 10-year performance and ongoing innovation with new fund launches, though concerns about AI market valuations and interest rate impacts create headwinds.
The outlook remains cautiously optimistic given QQQ's tech-heavy exposure to AI growth trends, but elevated valuations and macroeconomic sensitivity present near-term risks. Long-term growth potential persists through innovation leadership, though investors should monitor concentration risk in technology holdings and market volatility around Fed policy decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
